ARNI Again Shows Modest Benefits in HF With Mid-Range EF

(MedPage Today) -- Starting sacubitril/valsartan (Entresto) for recently decompensated heart failure with ejection fraction (EF) over 40% improved a key prognostic marker and, for those in the 40-60% range, clinical outcomes as well, the PARAGLIDE...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news